CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCT FOR CANCER THERAPY Russian patent published in 2024 - IPC C12N15/869 C12N15/33 A61K48/00 

FIELD: biotechnology.

SUBSTANCE: described is a recombinant oncolytic herpes simplex virus type 1 (HSV-1), comprising a HSV-1 vector containing a deletion modification in the wild-type HSV-1 genome, wherein said vector contains (i) only one copy of all represented in two copies of genes of HSV-1 genome of wild type, (ii) only one copy of duplicated non-coding sequences of genome HSV-1 of wild type, and (iii) sequences required for the expression of all wild-type HSV-1 genome open reading frames (ORF) presented in one copy, containing the ORF themselves regulatory sequences required for the expression of each ORF, wherein said regulatory sequences include promoters; a first heterologous nucleic acid sequence encoding IL-12; and a second nucleic acid sequence coding an anti-PD-1 agent, wherein said first and second nucleic acid sequences are stably inserted into at least a deleted region of the HSV-1 vector for treating various types of cancer. Also disclosed is a pharmaceutical composition for treating cancer, containing an effective amount of recombinant oncolytic HSV-1 and a pharmaceutically acceptable carrier.

EFFECT: invention extends the range of cancer treatment.

7 cl, 5 dwg, 1 tbl